John Lunger
Corporate Officer/Principal bei ADAPTIMMUNE THERAPEUTICS PLC
Vermögen: 162 784 $ am 31.05.2024
Aktive Positionen von John Lunger
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ADAPTIMMUNE THERAPEUTICS PLC | Corporate Officer/Principal | 01.03.2017 | - |
Karriereverlauf von John Lunger
Ehemalige bekannte Positionen von John Lunger
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| MERRIMACK PHARMACEUTICALS, INC. | Corporate Officer/Principal | - | - |
| GENOCEA BIOSCIENCES, INC. | Direktor/Vorstandsmitglied | 03.03.2022 | - |
| Independent Dir/Board Member | 03.03.2022 | - |
Ausbildung von John Lunger
| United States Naval Academy | Undergraduate Degree |
| The University of Chicago Booth School of Business | Masters Business Admin |
Statistik
International
| Vereinigte Staaten | 5 |
| Vereinigtes Königreich | 2 |
Operativ
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
| Masters Business Admin | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ADAPTIMMUNE THERAPEUTICS PLC | Health Technology |
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Merrimack Pharmaceuticals, Inc.
 Merrimack Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- John Lunger
- Erfahrung
